Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Astria Therapeutics (ATXS)
NASDAQ:ATXS
Astria Therapeutics (ATXS) Stock Price & Analysis
1,022 Followers
ATXS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.26 - $16.90
Previous Close$11.2
Volume30.70K
Average Volume (3M)569.31K
Market Cap
$621.62M
Enterprise Value$245.29M
Total Cash (Recent Filing)$369.91M
Total Debt (Recent Filing)$168.00K
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Aug 05, 2024EPS Estimate
-$0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.32
Shares Outstanding54,913,061
10 Day Avg. Volume473,655
30 Day Avg. Volume569,313
Standard Deviation0.30
R-Squared0.02
Alpha0.00992
Financial Highlights & Ratios
Price to Book (P/B)1.90
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.99
Forecast
1Y Price Target
$24.20Price Target Upside113.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Astria Therapeutics News
PremiumCompany Announcements
Astria Therapeutics Shareholders Meeting Decisions and Elections
PremiumCompany Announcements
Astria Therapeutics Expands Board, Appoints New Director
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAstria's lead asset STAR-0215 shows potential to be at least as effective as market leader Takhzyro, but with a more convenient dosing interval of every three or six months.
Efficacy And Safety DataAstria posted impressive six-month efficacy and safety data from its ALPHA-STAR Phase 1b/2 with STAR-0215, significantly de-risking the program for the upcoming pivotal Phase 3 trial.
Financial StrengthThe company ended the quarter financially strong with $369.9 million, which management believes is sufficient to fund current operations into mid-2027.
Bears Say
Competitive LandscapeThe disappointing results with the Q8W dose keep the competitive landscape door open for other prophylactic therapies in development.
Investor SentimentShares are down 35.2% since the data release on March 25 compared to a 10.5% decline for XBI in the same period.
ValuationThe totality of recent equity raises plus dilutive share counts need to be taken into consideration from a valuation standpoint.
---
Ownership Overview
12.29% Insiders
15.98% Mutual Funds
10.36% Other Institutional Investors
61.37% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ATXS FAQ
What was Astria Therapeutics’s price range in the past 12 months?
Astria Therapeutics lowest stock price was $4.26 and its highest was $16.90 in the past 12 months.
What is Astria Therapeutics’s market cap?
Currently, no data Available
When is Astria Therapeutics’s upcoming earnings report date?
Astria Therapeutics’s upcoming earnings report date is Aug 05, 2024 which is in 14 days.
How were Astria Therapeutics’s earnings last quarter?
Astria Therapeutics released its earnings results on May 09, 2024. The company reported -$0.38 earnings per share for the quarter, missing the consensus estimate of -$0.34 by -$0.04.
Is Astria Therapeutics overvalued?
According to Wall Street analysts Astria Therapeutics’s price is currently Undervalued.
Does Astria Therapeutics pay dividends?
Astria Therapeutics does not currently pay dividends.
What is Astria Therapeutics’s EPS estimate?
Astria Therapeutics’s EPS estimate is -$0.37.
How many shares outstanding does Astria Therapeutics have?
Astria Therapeutics has 54,913,060 shares outstanding.
What happened to Astria Therapeutics’s price movement after its last earnings report?
Astria Therapeutics reported an EPS of -$0.38 in its last earnings report, missing expectations of -$0.34. Following the earnings report the stock price went down -4.326%.
Which hedge fund is a major shareholder of Astria Therapeutics?
Among the largest hedge funds holding Astria Therapeutics’s share is Perceptive Advisors LLC. It holds Astria Therapeutics’s shares valued at 91M.
---
Astria Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.20 (113.78% Upside)
$24.20 (113.78% Upside)
Blogger Sentiment
Bearish
ATXS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 8.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.02%
12-Months-Change
Fundamentals
Return on Equity
-28.19%
Trailing 12-Months
Asset Growth
73.57%
Trailing 12-Months
Company Description
Astria Therapeutics
Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy. The company was founded by Michael R. Jirousek, Jill C. Milne, and Steven E. Shoelson on June 26, 2008 and is headquartered in Cambridge, MA.
---
ATXS Company Deck
---
ATXS Earnings Call
Q3 2023
0:00 / 0:00
---
ATXS Stock 12 Month Forecast
Average Price Target
$24.20
▲(113.78% Upside)
Technical Analysis
Best Analysts Covering ATXS
1 Year
1 Year Success Rate
10/17 ratings generated profit
1 Year Average Return
+26.22%
reiterated a buy rating 2 months ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 58.82% of your transactions generating a profit, with an average return of +26.22% per trade.
---